



Martinez II

#5  
UM  
2/24/87

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:  
DONALD S. ANSON, et al.  
Serial Number: 839,215  
Filed: March 13, 1986  
For: FACTOR IX PROTEIN

Docket: NRDC-17  
Group Art Unit: 127  
Date: February 11, 1987

SECOND INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

The Hon. Commissioner of Patents & Trademarks  
Washington, D.C. 20231

Sir:

Attached are a Form PTO 1449 and a copy of a reference which has recently come to applicant's attention. The reference is European Patent Specification 200421A (Zymogenetics, Inc.) which claims priority from two U.S. Patent Applications. The reference was published only recently, on December 10, 1986 but the two priority U.S. applications bear filing dates within the priority year of the present application.

The reference is concerned primarily with "stitching" a piece of Factor IX cDNA onto cDNA of Factor VIIa. Zymogenetics cloned a gene coding for Factor VIIa but it was incomplete, lacking the portion which encodes the calcium binding domain. They discovered that they could use the calcium binding domain of factor IX instead.

They therefore propose to ligate a piece of factor IX DNA to the factor VIIa to rectify the deficiency. However, Example 7 relates to the cloning and expression of a factor IX - like protein by itself.

Respectfully submitted  
MURRAY AND WHISENHUNT

By: 

Leonard C. Mitchard  
Reg. No. 29,009

906 Waterview Building  
1925 N. Lynn Street  
Arlington VA 22209  
(703) 243-0400  
Docket NRDC-17; LCM/bb

Attachments